The anti-TINAGL1 polyclonal antibody for breast cancer research

June 2022 (Nagoya City University Graduate School of Medical Sciences, Japan)

TINAGL1: a promising candidate biomarker and therapeutic target in breast cancer patients.

Tubulointerstitial nephritis antigen-like 1 (TINAGL1) suppresses tumor metastasis and growth in triple-negative breast cancer.

This study, led by Akiko Kato, Japan, aimed to determine the associations of TINAGL1 expression (both mRNA and protein) with clinicopathological factors and prognosis in breast cancer patients with long-term follow-up.

TINAGL1 protein expression was obtained by IHC on tissue from 299 breast cancer patients, while TINAGL1 mRNA expression was examined by RT-PCR in tissue from 599 breast cancer patients.

The results show that patients with low TINAGL1 mRNA expression have a worse prognosis. Moreover, low TINAGL1 mRNA expression is associated with significantly shorter disease-free survival.

Interestingly, no association was found between TINAGL1 protein expression and TINAGL1 mRNA expression. The survival analysis also showed no association between TINAGL1 protein expression and prognosis.

READ whole article here: https://lnkd.in/emQ-ydn4.

­čöČImage: TINAGL1 protein expression was localized in the cytoplasm of cancer cells. The anti-TINAGL1 polyclonal antibody (HPA048695) from Atlas Antibodies was used in the study.

The anti-TINAGL1 polyclonal antibody for breast cancer research